Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.

MLA

Meric-Bernstam, Funda, et al. “Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.” Journal of Clinical Oncology, vol. 42, no. 1, Jan. 2024, pp. 47–58. EBSCOhost, https://doi.org/10.1200/JCO.23.02005.

APA

Meric-Bernstam, F., Makker, V., Oaknin, A., Oh, D.-Y., Banerjee, S., González-Martín, A., Jung, K. H., Ługowska, I., Manso, L., Manzano, A., Melichar, B., Siena, S., Stroyakovskiy, D., Fielding, A., Ma, Y., Puvvada, S., Shire, N., & Lee, J.-Y. (2024). Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. Journal of Clinical Oncology, 42(1), 47–58. https://doi.org/10.1200/JCO.23.02005

Chicago

Meric-Bernstam, Funda, Vicky Makker, Ana Oaknin, Do-Youn Oh, Susana Banerjee, Antonio González-Martín, Kyung Hae Jung, et al. 2024. “Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.” Journal of Clinical Oncology 42 (1): 47–58. doi:10.1200/JCO.23.02005.